Compare iShares MSCI Indonesia ETF (EIDO) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs GSK plc — how do they compare? iShares MSCI Indonesia ETF trades at $11.89 (market cap $409.22M), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 224.5× iShares MSCI Indonesia ETF's market cap, and GSK plc pays a 3.9% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and GSK plc for 93 Days on average.
| EIDO | GSK | |
|---|---|---|
Market Cap | $409.22M | $91.88B |
Volume | 879,527 | 7,730,529 |
52-Week High | $19.22 | $61.18 |
52-Week Low | $10.80 | $43.24 |
Typical Hold Time | 76 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $11.67, down 1.6% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF's financial ratios are not disclosed in available data, but recent news highlights its exposure to Indonesian equities and a challenging technical downtrend. Trading volume remains active, though recent sessions show a decline from average levels.
The outlook for EIDO is cautious due to weak price action and sector concentration risks, with limited upside from low earnings growth. Key risks include dependence on financials and commodity markets, while potential opportunities may arise from seasonal trends or valuation rebounds if investor sentiment improves.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
